After the Department of Justice removed funding from the DEA for their marijuana enforcement, the DEA has asked the FDA to reschedule marijuana from a schedule I drug into something lesser.
This comes at a crucial time for marijuana companies and researchers, as the classification prevented any research of the drug to be done on US soil.
If the FDA removes marijuana from its list, that would open the doors for commercial development.
However, the considerations that the FDA must take before they act is a complex one. Marijuana is heavily politicized and is seen as the “gateway drug.” It also involves healthcare and criminal behavior. The road is a long one, but a small step is still progress.